Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND
[February 14, 2020]
Bukwang has recently received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase 2 clinical study of JM-010. JM-010, originating from a Danish bioventure company Contera Pharma, is currently under development for treating dyskinesia which emerges in up to 90% of Parkinson's disease patients following long term treatment of levodopa. Following acquisition of Con...
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
[November 13, 2019]
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseases including Alzheimer’s...
Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...